International Niemann–Pick Disease Alliance

Updates

  1. Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

    Orphazyme A/S in restructuring Company announcement No. 24/2022 Inside information www.orphazyme.com Company Registration No. 32266355 KemPharm to acquire Orphazyme assets, including those relating to the development and approval of arimoclomol, for a total of USD 12.8 million in cash and...

    Read story
  2. Pfrieger’s Digest – 06/2022 Edition

    “Pfrieger’s Digest” is written by Frank Pfrieger of Niemann-Pick Selbsthiifegruppe (Germany) to provide an overview of the latest advances in Niemann-Pick disease based on recent scientific publications. Frank Pfrieger is group leader at the Institute of Cellular and Integrative Neurosciences in...

    Read story
  3. Webinar: The impacts of olipudase alfa on pediatric patients with ASMD and their families

    We are pleased to be able to share the following collaborative webinar entitled The impacts of olipudase alfa on pediatric patients with ASMD and their families: Results of an international survey,  which was hosted by the International Niemann-Pick Disease Alliance (INPDA),...

    Read story
  4. Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency

    DOWNLOAD THE PDF VERSION Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency Xenpozyme represents first Sanofi therapy to be approved under the SAKIGAKE ‘fast-track’ designation Approval based on positive results from two separate clinical trials...

    Read story
  5. Orphazyme Update – March 2022

    We are writing to inform you that the CT-ORZY-NPC-002 trial activities as well as ongoing early-access and named-patient programs for arimoclomol in NPC will continue for the current time. As you may have seen, Orphazyme participated in an ad-hoc...

    Read story
  6. Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

    – Second Orphan Drug Designation Supports Azafaros’ Strategy to Develop AZ-3102 as a Disease Modifying Treatment in a Range of Severe Rare Inherited Metabolic Disorders – Leiden, The Netherlands, March 24, 2022 – Azafaros B.V. today announced that the...

    Read story
  7. Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C

    March 22, 2022 06:54 ET | Source: ORPHAZYME A/S Orphazyme A/S Company announcement No. 13/2022 Inside information www.orphazyme.com Company Registration No. 32266355 Decision to withdraw the European Marketing Authorisation Application comes ahead of scheduled final vote on the application later this month Orphazyme intends to request Type C Meeting with...

    Read story
  8. The Global Community supports INPDA’s letter to EMA

    The International Niemann-Pick Disease Alliance (INPDA) has organised a letter (see below) voicing the perspective and concerns of the NPC community, which will be sent to the European Medicines Agency (EMA) next week. Families also have the opportunity to...

    Read story
  9. Orphazyme Announces Update on Regulatory Review of Arimoclomol in the European Union

    Orphazyme A/S Company announcement No. 07/2022 Inside information www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA)...

    Read story
  10. IB1001-301: Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study

    We are pleased to share an update from IntraBio, regarding the clinical development of their lead drug, N-acetyl-L-leucine (IB1001) for NPC.  IntraBio is conducting a pivotal Phase III, randomized, double-blind, placebo-controlled trial for patients aged 4 years and older...

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...